secwatch / observer
8-K filed October 5, 2021, 7:59 PM ET ticker XERS CIK 0001867096
other material confidence high sentiment neutral materiality 0.75

Xeris Biopharma closes merger with Strongbridge; appoints new board and officers

Xeris Biopharma Holdings, Inc.

item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dawn Halkuff

Director
XERS · Xeris Biopharma Holdings, Inc.
Effective
2021-10-05
Filed
October 5, 2021, 7:59 PM ET
each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP
Appointed

John H. Johnson

Director
XERS · Xeris Biopharma Holdings, Inc.
Effective
2021-10-05
Filed
October 5, 2021, 7:59 PM ET
each of the following members of the Strongbridge board of directors was designated and appointed to the Board: John H. Johnson and Garheng Kong, M.D., PhD, MBA
Appointed

Steven Prestrelski

Chief Scientific Officer
XERS · Xeris Biopharma Holdings, Inc.
Effective
2021-10-05
Filed
October 5, 2021, 7:59 PM ET
the Board appointed (i) John Shannon as President and Chief Operating Officer, (ii) Kenneth Johnson, Pharm.D., as Senior Vice President, Global Development and Medical Affairs, (iii) Beth P. Hecht as Senior Vice President, Chief Legal Officer& Corporate Secretary, and (iv) Steven Prestrelski, Ph.D. as Chief Scientific Officer
Appointed

BJ Bormann

Director
XERS · Xeris Biopharma Holdings, Inc.
Effective
2021-10-05
Filed
October 5, 2021, 7:59 PM ET
each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP
Appointed

John Shannon

President and Chief Operating Officer
XERS · Xeris Biopharma Holdings, Inc.
Effective
2021-10-05
Filed
October 5, 2021, 7:59 PM ET
the Board appointed (i) John Shannon as President and Chief Operating Officer, (ii) Kenneth Johnson, Pharm.D., as Senior Vice President, Global Development and Medical Affairs, (iii) Beth P. Hecht as Senior Vice President, Chief Legal Officer& Corporate Secretary, and (iv) Steven Prestrelski, Ph.D. as Chief Scientific Officer
Appointed

Beth P. Hecht

Senior Vice President, Chief Legal Officer & Corporate Secretary
XERS · Xeris Biopharma Holdings, Inc.
Effective
2021-10-05
Filed
October 5, 2021, 7:59 PM ET
the Board appointed (i) John Shannon as President and Chief Operating Officer, (ii) Kenneth Johnson, Pharm.D., as Senior Vice President, Global Development and Medical Affairs, (iii) Beth P. Hecht as Senior Vice President, Chief Legal Officer& Corporate Secretary, and (iv) Steven Prestrelski, Ph.D. as Chief Scientific Officer
Appointed

John Schmid

Director
XERS · Xeris Biopharma Holdings, Inc.
Effective
2021-10-05
Filed
October 5, 2021, 7:59 PM ET
each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP
Appointed

Jeffrey W. Sherman

Director
XERS · Xeris Biopharma Holdings, Inc.
Effective
2021-10-05
Filed
October 5, 2021, 7:59 PM ET
each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP
Appointed

Kenneth Johnson

Senior Vice President, Global Development and Medical Affairs
XERS · Xeris Biopharma Holdings, Inc.
Effective
2021-10-05
Filed
October 5, 2021, 7:59 PM ET
the Board appointed (i) John Shannon as President and Chief Operating Officer, (ii) Kenneth Johnson, Pharm.D., as Senior Vice President, Global Development and Medical Affairs, (iii) Beth P. Hecht as Senior Vice President, Chief Legal Officer& Corporate Secretary, and (iv) Steven Prestrelski, Ph.D. as Chief Scientific Officer
Appointed

Marla S. Persky

Director
XERS · Xeris Biopharma Holdings, Inc.
Effective
2021-10-05
Filed
October 5, 2021, 7:59 PM ET
each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP
Appointed

Garheng Kong

Director
XERS · Xeris Biopharma Holdings, Inc.
Effective
2021-10-05
Filed
October 5, 2021, 7:59 PM ET
each of the following members of the Strongbridge board of directors was designated and appointed to the Board: John H. Johnson and Garheng Kong, M.D., PhD, MBA

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dawn Halkuff was appointed as Director at Xeris Biopharma Holdings, Inc..

Action
appointed
Role
Director
Exact text from the filing
each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

John H. Johnson was appointed as Director at Xeris Biopharma Holdings, Inc..

Action
appointed
Role
Director
Exact text from the filing
each of the following members of the Strongbridge board of directors was designated and appointed to the Board: John H. Johnson and Garheng Kong, M.D., PhD, MBA
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Steven Prestrelski was appointed as Chief Scientific Officer at Xeris Biopharma Holdings, Inc..

Action
appointed
Role
Chief Scientific Officer
Exact text from the filing
the Board appointed (i) John Shannon as President and Chief Operating Officer, (ii) Kenneth Johnson, Pharm.D., as Senior Vice President, Global Development and Medical Affairs, (iii) Beth P. Hecht as Senior Vice President, Chief Legal Officer& Corporate Secretary, and (iv) Steven Prestrelski, Ph.D. as Chief Scientific Officer
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

BJ Bormann was appointed as Director at Xeris Biopharma Holdings, Inc..

Action
appointed
Role
Director
Exact text from the filing
each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

John Shannon was appointed as President and Chief Operating Officer at Xeris Biopharma Holdings, Inc..

Action
appointed
Role
President and Chief Operating Officer
Exact text from the filing
the Board appointed (i) John Shannon as President and Chief Operating Officer, (ii) Kenneth Johnson, Pharm.D., as Senior Vice President, Global Development and Medical Affairs, (iii) Beth P. Hecht as Senior Vice President, Chief Legal Officer& Corporate Secretary, and (iv) Steven Prestrelski, Ph.D. as Chief Scientific Officer
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Beth P. Hecht was appointed as Senior Vice President, Chief Legal Officer & Corporate Secretary at Xeris Biopharma Holdings, Inc..

Action
appointed
Role
Senior Vice President, Chief Legal Officer & Corporate Secretary
Exact text from the filing
the Board appointed (i) John Shannon as President and Chief Operating Officer, (ii) Kenneth Johnson, Pharm.D., as Senior Vice President, Global Development and Medical Affairs, (iii) Beth P. Hecht as Senior Vice President, Chief Legal Officer& Corporate Secretary, and (iv) Steven Prestrelski, Ph.D. as Chief Scientific Officer
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

John Schmid was appointed as Director at Xeris Biopharma Holdings, Inc..

Action
appointed
Role
Director
Exact text from the filing
each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey W. Sherman was appointed as Director at Xeris Biopharma Holdings, Inc..

Action
appointed
Role
Director
Exact text from the filing
each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Kenneth Johnson was appointed as Senior Vice President, Global Development and Medical Affairs at Xeris Biopharma Holdings, Inc..

Action
appointed
Role
Senior Vice President, Global Development and Medical Affairs
Exact text from the filing
the Board appointed (i) John Shannon as President and Chief Operating Officer, (ii) Kenneth Johnson, Pharm.D., as Senior Vice President, Global Development and Medical Affairs, (iii) Beth P. Hecht as Senior Vice President, Chief Legal Officer& Corporate Secretary, and (iv) Steven Prestrelski, Ph.D. as Chief Scientific Officer
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Marla S. Persky was appointed as Director at Xeris Biopharma Holdings, Inc..

Action
appointed
Role
Director
Exact text from the filing
each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Garheng Kong was appointed as Director at Xeris Biopharma Holdings, Inc..

Action
appointed
Role
Director
Exact text from the filing
each of the following members of the Strongbridge board of directors was designated and appointed to the Board: John H. Johnson and Garheng Kong, M.D., PhD, MBA
View on SEC.gov

Xeris Biopharma Holdings, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-21-292225
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.